BloggingStocks http://www.bloggingstocks.com BloggingStocks http://www.blogsmithmedia.com/http://www.bloggingstocks.com/media/feedlogo.gif BloggingStocks http://www.bloggingstocks.com en-us Copyright 2012 Weblogs, Inc. The contents of this feed are available for non-commercial use only. Blogsmith http://www.blogsmith.com/<![CDATA[Johnson & Johnson Re-Trenches to $60]]>http://www.bloggingstocks.com/2011/03/08/johnson-and-johnson-re-trenches-to-60/http://www.bloggingstocks.com/2011/03/08/johnson-and-johnson-re-trenches-to-60/http://www.bloggingstocks.com/2011/03/08/johnson-and-johnson-re-trenches-to-60/#commentsFiled under: ,

The shares of health care products and pharmaceutical giant (JNJ) continue to aggravate and consternate.

JNJ, first discussed here on May 20, 2010 at a price of $55.87, formed a double-bottom last summer, after which the shares re-took the $60 level, rose to $65, only to retreat this winter to $60.

The sell/stop loss is not far away at $56, and the way JNJ has performed, some investors with long positions are probably rooting for it. I would argue that JNJ has one more chance to break through $70 this year, or the position will be closed.

From a fundamental standpoint, JNJ's revenue should increase 3% to 4% in FY2011, despite some sales erosion to generics. Meanwhile, new orthopedic and cardiovascular products should help the company's medical device unit perform adequately in 2011. A 2% to 3% revenue rise also is seen for FY2012.

Continue reading Johnson & Johnson Re-Trenches to $60

Johnson & Johnson Re-Trenches to $60 originally appeared on BloggingStocks on Tue, 08 Mar 2011 09:30:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>featuredjnjJohnsonJohnsonpharmaceutical stockspharmaceuticalsTue, 08 Mar 2011 09:30:00 EST<![CDATA[MannKind's Inhaled Insulin Verdict Delayed by FDA]]>http://www.bloggingstocks.com/2010/12/28/mannkinds-inhaled-insulin-verdict-delayed-by-fda/http://www.bloggingstocks.com/2010/12/28/mannkinds-inhaled-insulin-verdict-delayed-by-fda/http://www.bloggingstocks.com/2010/12/28/mannkinds-inhaled-insulin-verdict-delayed-by-fda/#commentsFiled under:

MannKind (MNKD) logoPharmaceutical company MannKind (MNKD) shares have traded considerably higher this morning, gaining 9% shortly after the opening bell and trading in the upper $8 region. It appears that the rally was sparked by news that the U.S. Federal Drug Administration would not be able to complete a review of the company's inhaled insulin Afrezza by December 29.

The FDA added that it will need roughly four more weeks to complete the review. Back in July, the FDA accepted a resubmission on Afrezza and classified it a class 2 response.

Continue reading MannKind's Inhaled Insulin Verdict Delayed by FDA

MannKind's Inhaled Insulin Verdict Delayed by FDA originally appeared on BloggingStocks on Tue, 28 Dec 2010 10:00:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>diabetesFDAinthenewsMannKindMNKDpharmaceutical stockspharmaceuticalstechnical analysisTue, 28 Dec 2010 10:00:00 EST<![CDATA[Pfizer's Q3 Earnings Fall 70% on Charges]]>http://www.bloggingstocks.com/2010/11/02/pfizers-q3-earnings-fall-70-on-charges/http://www.bloggingstocks.com/2010/11/02/pfizers-q3-earnings-fall-70-on-charges/http://www.bloggingstocks.com/2010/11/02/pfizers-q3-earnings-fall-70-on-charges/#commentsFiled under: ,

Pharmaceutical firm Pfizer (PFE) announced third-quarter earnings this morning, reporting that large charges pulled its profit 70% lower than a year ago. The pfunnily spelled pfarmaceutical pfirm reported that net income came in at $866 million, or 11 cents per share, down from $2.88 billion, or 43 cents per share, a year ago.

Taking one-time items out of the equation, Pfizer earned $4.37 billion, or 54 cents per share, topping the consensus estimate by three cents.

Continue reading Pfizer's Q3 Earnings Fall 70% on Charges

Pfizer's Q3 Earnings Fall 70% on Charges originally appeared on BloggingStocks on Tue, 02 Nov 2010 09:30:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>featuredinthenewsPFEPfizerpharmaceutical stockspharmaceuticalstechnical analysisTue, 02 Nov 2010 09:30:00 EST<![CDATA[Genzyme Rejects Sanofi-Aventis's Buyout Proposal]]>http://www.bloggingstocks.com/2010/08/30/genzyme-rejects-sanofi-aventiss-buyout-proposal/http://www.bloggingstocks.com/2010/08/30/genzyme-rejects-sanofi-aventiss-buyout-proposal/http://www.bloggingstocks.com/2010/08/30/genzyme-rejects-sanofi-aventiss-buyout-proposal/#commentsFiled under: ,

Over the weekend, French pharmaceutical firm Sanofi-Aventis (SNY) made its attempt to take over biotech firm Genzyme (GENZ) official. SNY offered $69 per GENZ share, which is slightly more than a dollar higher over GENZ's Friday close. The total value of the offer comes to $18.5 billion.

Although the offer isn't much more than Friday's close, it is 38% higher than GENZ's July 1 close. This is when speculation cropped up about a potential buyout offer from SNY. GENZ turned down the offer, noting that SNY was undervaluing the company.

Continue reading Genzyme Rejects Sanofi-Aventis's Buyout Proposal

Genzyme Rejects Sanofi-Aventis's Buyout Proposal originally appeared on BloggingStocks on Mon, 30 Aug 2010 10:00:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>biotechbuyoutinthenewspharmaceuticalsSanofi AventisSNYtakeoverMon, 30 Aug 2010 10:00:00 EST<![CDATA[Allergan Rallies on News of License Agreement]]>http://www.bloggingstocks.com/2010/08/25/allergan-rallies/http://www.bloggingstocks.com/2010/08/25/allergan-rallies/http://www.bloggingstocks.com/2010/08/25/allergan-rallies/#commentsFiled under:

Allergan logoAs the opening bell sounded and stocks got off to a sluggish start, I decided to take a look for stocks that got off to a fast start. One of those stocks is Botox-maker Allergan (AGN). In early trading, the pharmaceutical firm was more than a percentage point higher, so I took to digging to find out why.

The biggest news I found for Allergan was that it entered into an Amended and Restated License, Development and Marketing Agreement with Inspire Pharmaceuticals. The agreement deals with terms related to the Prolacria 2% development program and Inspire's right to receive revenues from Allergan relating to net sales of Restasis and any other human opthalmic formulations of cyclosporine owned or controlled by Allergan. Simply put, Inspire will receive revenues on net sales of Restasis and any related cyclosporine-based medicines.

Continue reading Allergan Rallies on News of License Agreement

Allergan Rallies on News of License Agreement originally appeared on BloggingStocks on Wed, 25 Aug 2010 10:30:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>AGNAllerganbotoxfeaturedInspire PharmaceuticalsinthenewspharmaceuticalpharmaceuticalsRestasistechnical analysisWed, 25 Aug 2010 10:30:00 EST<![CDATA[Looking to Play Defense? Buy Pfizer]]>http://www.bloggingstocks.com/2010/08/03/looking-to-play-defense-buy-pfizer-pfe/http://www.bloggingstocks.com/2010/08/03/looking-to-play-defense-buy-pfizer-pfe/http://www.bloggingstocks.com/2010/08/03/looking-to-play-defense-buy-pfizer-pfe/#commentsFiled under: ,

Pfizer Inc. (PFE) reported a blowout second quarter this morning prior to the opening bell. Net income attributable to the company increased to $2.475 billion compared to $2.261 billion in the year-ago quarter. On an adjusted basis, quarterly earnings were $4.959 billion, or $0.62 per share, versus $3.249 billion or $0.48 per share, in last year's corresponding quarter. This compared to Wall Street analysts' consensus EPS estimates of $0.52.

Revenues were up 58% to $17.327 billion which came in way ahead of analysts' estimates of $16.65 billion. The company also reaffirmed its 2010 EPS guidance of $2.10 to $2.20 and said it expects earnings to come in at the higher end of that range. Using these metrics, PFE looks ridiculously cheap (and has been for sometime). The stock has been a favorite of value investors such as David Einhorn because of its blue-chip brand, inexpensive valuation, fat dividend yield, and defensive business profile.

Continue reading Looking to Play Defense? Buy Pfizer

Looking to Play Defense? Buy Pfizer originally appeared on BloggingStocks on Tue, 03 Aug 2010 17:20:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>drugsfeaturedhealth carehealthcareinthenewslong tradingPFEpfizerpharmaceuticalsTue, 03 Aug 2010 17:20:00 EST<![CDATA[Closing Bell: Markets Still Acting Range-Bound (KGC, PG, PFE, DOW, CTSH, RIMM)]]>http://www.bloggingstocks.com/2010/08/03/closing-bell-markets-still-acting-range-bound-kgc-pg-pfe-do/http://www.bloggingstocks.com/2010/08/03/closing-bell-markets-still-acting-range-bound-kgc-pg-pfe-do/http://www.bloggingstocks.com/2010/08/03/closing-bell-markets-still-acting-range-bound-kgc-pg-pfe-do/#commentsFiled under: , ,

Today's stock market could not offer a repeat of triple-digit DJIA gains. Personal income and spending failed to offer a renewed hope that a major upside was coming from Joe Public in new consumer spending. The pending home sales data is also running at historic lows.

Here are today's unofficial closing bell levels:

Dow Jones 10,636.38 -38.00 (-0.36%)
S&P 500 1,120.46 -5.40 (-0.48%)
Nasdaq 2,283.52 -11.84 (-0.52%)

Top Analyst Calls

Continue reading Closing Bell: Markets Still Acting Range-Bound (KGC, PG, PFE, DOW, CTSH, RIMM)

Closing Bell: Markets Still Acting Range-Bound (KGC, PG, PFE, DOW, CTSH, RIMM) originally appeared on BloggingStocks on Tue, 03 Aug 2010 16:20:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>blackberryblackberry 6Blackberry6cognizant technologyCognizantTechnologyconsumer spendingCTSHDOWgoldKGCkinross goldKinrossGoldPFEpharmaceuticalsred back minesRIMMTorchTue, 03 Aug 2010 16:20:00 EST<![CDATA[Wall Street Ignoring Big Pharma -- Should You?]]>http://www.bloggingstocks.com/2010/06/28/wall-street-ingoring-big-pharma-should-you/http://www.bloggingstocks.com/2010/06/28/wall-street-ingoring-big-pharma-should-you/http://www.bloggingstocks.com/2010/06/28/wall-street-ingoring-big-pharma-should-you/#commentsFiled under: , , , ,

In its weekend edition, Barron's Andrew Bary wonders whether Big Pharma's punishment on Wall Street has gone too far. The sector has fallen out of favor with Wall Street and now has one of the lowest price/earnings ratios of any major sector of the stock market, Bary writes.

Investors are staying away from the large pharmaceutical companies ahead of their looming patent cliff, when blockbuster drugs like Lipitor, Plavix and Singulair lose patent protection and lose most of the sales from these drugs to generics. Investors also fear the companies don't have enough new drugs in the pipeline to make up for the lost sales, which could mean big hits to earnings.

But when the Street writes off one of the world's most important industries and with valuations at all-time lows, investors ought to take notice, Bary says. Especially when the average dividend yield of the big drugmakers is 4.8%.

Continue reading Wall Street Ignoring Big Pharma -- Should You?

Wall Street Ignoring Big Pharma -- Should You? originally appeared on BloggingStocks on Mon, 28 Jun 2010 14:30:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>aznbig pharmabmyfeaturedgskinthenewsllymrknvspatent cliffpfepharmaceuticalsrhhbysnyMon, 28 Jun 2010 14:30:00 EST<![CDATA[Johnson & Johnson a Safe Buy?]]>http://www.bloggingstocks.com/2010/06/11/johnson-and-johnson-a-safe-buy/http://www.bloggingstocks.com/2010/06/11/johnson-and-johnson-a-safe-buy/http://www.bloggingstocks.com/2010/06/11/johnson-and-johnson-a-safe-buy/#commentsFiled under:

It looks like some members in Congress are not too happy about the way Johnson & Johnson (JNJ) has behaved in the aftermath of the recent recalls involving some medicinal products.

That may be, but I'll tell you, the stock is trading with a pretty cool dividend yield attached right now. At the time of this writing, shares were exchanging hands during the afternoon session at a price of $58.12. That means that the yield is about 3.7%.

Continue reading Johnson & Johnson a Safe Buy?

Johnson & Johnson a Safe Buy? originally appeared on BloggingStocks on Fri, 11 Jun 2010 17:00:00 EST. Please see our terms for use of feeds.

Read | Permalink | Email this | Comments]]>dividend investingdividend stocksJNJjohnson and johnsonpharmaceuticalsFri, 11 Jun 2010 17:00:00 EST<![CDATA[$75 Million in Drugs Stolen from Eli Lilly Warehouse]]>http://www.bloggingstocks.com/2010/03/18/75-million-in-drugs-stolen-from-eli-lilly-warehouse/http://www.bloggingstocks.com/2010/03/18/75-million-in-drugs-stolen-from-eli-lilly-warehouse/http://www.bloggingstocks.com/2010/03/18/75-million-in-drugs-stolen-from-eli-lilly-warehouse/#commentsFiled under:

Eli Lilly (LLY) announced Wednesday that burglars broke into a Connecticut-based warehouse over the weekend and stole roughly $75 million in prescription drugs. According to police, the break-in happened either late Saturday or early Sunday. According to LLY, "dozens of pallets" of antidepressants were stolen, including Prozac, Cymbalta, Zyprexa (an anti-psychotic), and other medicines. The police called the theft a "well-planned event."

The company stated that it is working with the U.S. FDA Office of Criminal Investigations and other law enforcement officials. LLY's senior vice president of global equity noted that the company has "taken quick and appropriate actions to ensure the safety of our medicines." The company added that the "U.S. pharmaceutical distribution system is tightly controlled and monitored, making it extremely difficult for stolen product to make it to patients through legitimate channels."

Continue reading $75 Million in Drugs Stolen from Eli Lilly Warehouse

$75 Million in Drugs Stolen from Eli Lilly Warehouse originally appeared on BloggingStocks on Thu, 18 Mar 2010 09:30:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>crimedrugsEli LillyfeaturedinthenewsLLYpharmaceuticalstheftThu, 18 Mar 2010 09:30:00 EST<![CDATA[Pfizer Sees Some Disappointing Study Results]]>http://www.bloggingstocks.com/2010/03/12/pfizer-sees-some-disappointing-study-results/http://www.bloggingstocks.com/2010/03/12/pfizer-sees-some-disappointing-study-results/http://www.bloggingstocks.com/2010/03/12/pfizer-sees-some-disappointing-study-results/#commentsFiled under:

Late Thursday, Pfizer (PFE) announced that two of its late-stage studies of an approved kidney cancer drug failed to treat breast cancer significantly. Reportedly, two studies of kidney cancer drug Sutent did not show a significant benefit to advanced breast cancer patients when combined with chemotherapy.

This news is definitely a setback for PFE, as it was hoped that Sutent could demonstrate a significant benefit when combined with chemotherapy as opposed to treatment by chemotherapy alone.

Continue reading Pfizer Sees Some Disappointing Study Results

Pfizer Sees Some Disappointing Study Results originally appeared on BloggingStocks on Fri, 12 Mar 2010 10:30:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>cancercancer treatmentdrug studiesdrugsfeaturedinthenewspfepfizerpharmaceuticalsFri, 12 Mar 2010 10:30:00 EST<![CDATA[Closing Bell: Stumbling About (AIG, SII, SLB XNPT)]]>http://www.bloggingstocks.com/2010/02/22/closing-bell-stumbling-about-aig-sii-slb-xnpt/http://www.bloggingstocks.com/2010/02/22/closing-bell-stumbling-about-aig-sii-slb-xnpt/http://www.bloggingstocks.com/2010/02/22/closing-bell-stumbling-about-aig-sii-slb-xnpt/#commentsFiled under: , , , , ,

The market slipped in and out of a stupor today as traders tried to decide whether the new $980 billion health care reform bill will help or hurt the economy if it passes.

Today's unofficial closing numbers:

Dow 10,382.63 -19.72 (-0.19%)
S&P 500 1,108.01 -1.16 (-0.10%)
Nasdaq 2,242.03 -1.84 (-0.08%)

Continue reading Closing Bell: Stumbling About (AIG, SII, SLB XNPT)

Closing Bell: Stumbling About (AIG, SII, SLB XNPT) originally appeared on BloggingStocks on Mon, 22 Feb 2010 16:00:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>healthcarereformPharmaceuticalsxenoportMon, 22 Feb 2010 16:00:00 EST<![CDATA[Pfizer Discontinues Study of Cancer Drug]]>http://www.bloggingstocks.com/2009/12/30/pfizer-discontinues-study-of-cancer-drug/http://www.bloggingstocks.com/2009/12/30/pfizer-discontinues-study-of-cancer-drug/http://www.bloggingstocks.com/2009/12/30/pfizer-discontinues-study-of-cancer-drug/#commentsFiled under: ,

Late Tuesday, pharmaceutical firm Pfizer (PFE) announced the discontinuation of A4021016, a Phase 3 trial that was examining the effects of figitumumab. Figitumumab is an investigational compound that is used as a first-line treatment in patients with advanced non-adenocarcinoma non-small cell lung cancer (NSCLC).

The study was terminated because it met predefined boundaries for early termination. The Data Safety Monitoring Committee (DSMC) found that the addition of figitumumab to paclitaxel plus carboplatin would be unlikely to meet the primary endpoint of the study.

Continue reading Pfizer Discontinues Study of Cancer Drug

Pfizer Discontinues Study of Cancer Drug originally appeared on BloggingStocks on Wed, 30 Dec 2009 11:40:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>DowinthenewsPFEPfizerpharmaceutical stockspharmaceutical studiespharmaceuticalsWed, 30 Dec 2009 11:40:00 EST<![CDATA[Abbott Labs wishes upon a StarLIMS]]>http://www.bloggingstocks.com/2009/12/15/abbott-labs-wishes-upon-a-starlims/http://www.bloggingstocks.com/2009/12/15/abbott-labs-wishes-upon-a-starlims/http://www.bloggingstocks.com/2009/12/15/abbott-labs-wishes-upon-a-starlims/#commentsFiled under: ,

Bright and early this morning, lab-technology innovator StarLIMS (LIMS) announced that it will be bought by pharmaceutical firm Abbott Laboratories (ABT) for roughly $123 million. This purchase price reflects a per-share price tag of $14 for LIMS, which closed Monday's trading session near the $10 region.

Needless to say, LIMS was the subject of heavy pre-market trading, which pushed the per-share price closer to the premium paid by ABT. According to the report, ABT will acquire all outstanding equity of LIMS, which currently has roughly $18 million cash in hand.

Continue reading Abbott Labs wishes upon a StarLIMS

Abbott Labs wishes upon a StarLIMS originally appeared on BloggingStocks on Tue, 15 Dec 2009 10:40:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>abbott laboratoriesabtinthenewslimspharmaceuticalpharmaceuticalspurchasestarlimstakeoverTue, 15 Dec 2009 10:40:00 EST<![CDATA[Bristol-Myers Squibb is in an uptrend]]>http://www.bloggingstocks.com/2009/12/03/bristol-myers-squibb-is-in-an-uptrend/http://www.bloggingstocks.com/2009/12/03/bristol-myers-squibb-is-in-an-uptrend/http://www.bloggingstocks.com/2009/12/03/bristol-myers-squibb-is-in-an-uptrend/#commentsFiled under: ,

Biopharmaceutical company Bristol-Myers Squibb (BMY) is performing on schedule, which is why I'm reiterating my buy rating for the company's shares, first recommended on June 1, 2009 at a price of $20.11. If you bought BMY in June, you're up about 24%.

Look for a 6-8% revenue increase for BMY in 2010, boosted by revenue gains in key proprietary drugs, led by Plavix (for the prevention of stroke, heart attack, and vascular disease). Also look for impressive results from new products Orencia (for rheumatoid arthritis) and Sprycel (for leukemia); BMY's nutritional products also should register a good year. The First Call FY2009/FY2010 EPS estimates for BMY are $2.02 to $2.21.

Continue reading Bristol-Myers Squibb is in an uptrend

Bristol-Myers Squibb is in an uptrend originally appeared on BloggingStocks on Thu, 03 Dec 2009 17:15:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>orenciapharmaceuticalsplavixsprycelThu, 03 Dec 2009 17:15:00 EST<![CDATA[Pfizer reports solid quarterly earnings thanks to cost-cutting maneuvers]]>http://www.bloggingstocks.com/2009/10/20/pfizer-reports-solid-quarterly-earnings-thanks-to-cost-cutting-m/http://www.bloggingstocks.com/2009/10/20/pfizer-reports-solid-quarterly-earnings-thanks-to-cost-cutting-m/http://www.bloggingstocks.com/2009/10/20/pfizer-reports-solid-quarterly-earnings-thanks-to-cost-cutting-m/#commentsFiled under: ,

On Tuesday, Pfizer (NYSE: PFE) stepped into the earnings spotlight, announcing a higher third-quarter profit compared to last year. The pharmaceutical firm earned 43 cents per share, or 51 cents per share in adjusted earnings. A year ago, PFE earned 34 cents per share before item exclusions. The Street expected PFE to report third-quarter earnings of 48 cents per share excluding items.

Quarterly revenue checked in at $11.62 billion, 3% lower than last year's third-quarter revenue. Revenue was pulled roughly 5% lower due to unfavorable foreign exchange rates.

Continue reading Pfizer reports solid quarterly earnings thanks to cost-cutting maneuvers

Pfizer reports solid quarterly earnings thanks to cost-cutting maneuvers originally appeared on BloggingStocks on Tue, 20 Oct 2009 09:30:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>featuredintegrationjob lossesJobLossesjobsmedicinepfePfizerpharmaceutical sectorpharmaceuticalsPharmaceuticalSectorWyethTue, 20 Oct 2009 09:30:00 EST<![CDATA[Abbott Laboratories posts solid earnings results]]>http://www.bloggingstocks.com/2009/10/14/abbott-laboratories-posts-solid-earnings-results/http://www.bloggingstocks.com/2009/10/14/abbott-laboratories-posts-solid-earnings-results/http://www.bloggingstocks.com/2009/10/14/abbott-laboratories-posts-solid-earnings-results/#commentsFiled under: , ,

Plenty of companies are reporting earnings this Wednesday morning, one of which is Abbott Laboratories (NYSE: ABT).

The health-care giant reported third-quarter earnings of 95 cents per share, far better than last year's 69 cents per share. Taking items out of the equation, Abbott would have earned 92 cents per share, which is two cents better than the consensus estimate. Quarterly revenue matched the consensus estimate for $7.76 billion.

Continue reading Abbott Laboratories posts solid earnings results

Abbott Laboratories posts solid earnings results originally appeared on BloggingStocks on Wed, 14 Oct 2009 12:00:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>Abbott LaboratoriesABTearningsforecastHumirainthenewspharmaceuticalsWed, 14 Oct 2009 12:00:00 EST<![CDATA[Johnson & Johnson (JNJ) posts disappointing revenue numbers]]>http://www.bloggingstocks.com/2009/10/13/johnson-and-johnson-jnj-posts-disappointing-revenue-numbers/http://www.bloggingstocks.com/2009/10/13/johnson-and-johnson-jnj-posts-disappointing-revenue-numbers/http://www.bloggingstocks.com/2009/10/13/johnson-and-johnson-jnj-posts-disappointing-revenue-numbers/#commentsFiled under: , , , , , , , ,

Johnson & Johnson (NYSE: JNJ) reported its third quarter figures this morning, and while the company managed to post better than expected earnings, its revenues were lower than analysts had expected.

Going into this morning's earnings report analysts had estimated J&J would earn $1.13 per share in the third quarter. The company was able to put up better than expected earnings results, saying it earned $1.20 per share in the quarter. But revenues disappointed. Analysts had forecast the company's revenues would be $15.22 billion in the quarter, but actual revenues were below estimates at $15.08 billion.

Continue reading Johnson & Johnson (JNJ) posts disappointing revenue numbers

Johnson & Johnson (JNJ) posts disappointing revenue numbers originally appeared on BloggingStocks on Tue, 13 Oct 2009 10:10:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>bad earningsBadEarningsearningsfeaturedJNJjohnson and johnsonJohnsonAndJohnsonpharmaceuticalsrevenuesTue, 13 Oct 2009 10:10:00 EST<![CDATA[Seize the day with JNJ]]>http://www.bloggingstocks.com/2009/09/18/seize-the-day-with-jnj/http://www.bloggingstocks.com/2009/09/18/seize-the-day-with-jnj/http://www.bloggingstocks.com/2009/09/18/seize-the-day-with-jnj/#commentsFiled under: ,

I'm reiterating my Buy rating for Johnson & Johnson (NYSE: JNJ), first recommended on May 20, 2009 at a price of $55.87.

The value proposition with Johnson & Johnson 'isn't rocket science', as they say, even though the business model does involve a considerable amount of science.

Continue reading Seize the day with JNJ

Seize the day with JNJ originally appeared on BloggingStocks on Fri, 18 Sep 2009 18:00:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>johnson and johnsonJohnsonAndJohnsonpharmaceuticalssciencestentsFri, 18 Sep 2009 18:00:00 EST<![CDATA[Eli Lilly to restructure, bet on drug portfolio]]>http://www.bloggingstocks.com/2009/09/15/eli-lilly-to-restructure-bet-on-drug-portfolio/http://www.bloggingstocks.com/2009/09/15/eli-lilly-to-restructure-bet-on-drug-portfolio/http://www.bloggingstocks.com/2009/09/15/eli-lilly-to-restructure-bet-on-drug-portfolio/#commentsFiled under: , ,

Pharmaceutical company Eli Lilly & Co. (NYSE: LLY) is planning to cut 5,500 jobs over the next few years and reorganize into five business units. The company is looking to reduce costs and accelerate how long it takes new drugs to get to market, especially as its top performers see their patents expire. This translates to a workforce reduction of close to 14% - to 35,000. This measure doesn't include new positions in emerging markets with high potential and Japan.

The company hopes to cut as much as possible through attrition and retirements - and it would not indicate how many other positions would have to be cut.

Eli Lilly's goal is to slash its annual cost by $1 billion during this restructuring. The new business units will be: cancer, diabetes, established markets, emerging markets and Elanco, which is its animal health business. This is a change from the existing functional model, which separates U.S. and global marketing for each drug in the company's portfolio. Through the new structure, Lilly says, drug development and marketing will be tied more closely.

Continue reading Eli Lilly to restructure, bet on drug portfolio

Eli Lilly to restructure, bet on drug portfolio originally appeared on BloggingStocks on Tue, 15 Sep 2009 10:40:00 EST. Please see our terms for use of feeds.

Read | Permalink | Email this | Comments]]>cancercancer drugsCancerDrugscymbaltadiabetesdiabetes drugsDiabetesDrugseli lillyeli lilly and coemerging marketsEmergingMarketsfeaturedgemzarhumalogllymultiple sclerosisnew drugsNewDrugspharmaceutical stockspharmaceuticalsPharmaceuticalStockszyprexaTue, 15 Sep 2009 10:40:00 EST